Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
作者： Russell J. Schilder , Harsh B. Pathak , Anna E. Lokshin , Robert W. Holloway , Ronald D. Alvarez
DOI: 10.1016/J.YGYNO.2008.12.003
关键词:
摘要: Objectives Determine if cetuximab dose escalation to induce grade 2 rash correlates with anti-tumor activity and sera-based markers could predict likelihood of response.
gynecologiconcology-online.net
elsevier.com
sci-hub.se 参考文章(73)
Robert B Diasio, Jeanne Fourie, Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. Drugs. ,vol. 66, pp. 1441- 1463 ,(2006) , 10.2165/00003495-200666110-00003
Robert C. Bast, Molly Brewer, Changping Zou, Mary A. Hernandez, Mary Daley, Robert Ozols, Karen Lu, Zhen Lu, Donna Badgwell, Gordon B. Mills, Steven Skates, Zhen Zhang, Dan Chan, Anna Lokshin, Yinhua Yu, Prevention and Early Detection of Ovarian Cancer: Mission Impossible? Recent results in cancer research. ,vol. 174, pp. 91- 100 ,(2007) , 10.1007/978-3-540-37696-5_9
Robert C. Young, William J. Hoskins, Carlos A. Perez, Principles and Practice of Gynecologic Oncology ,(1992)
Marleen van Gramberen, Stefano Fracchioli, Andreas Scorilas, Marco Massobrio, Ulf-Hakan Stenman, Dionyssios Katsaros, Roberto Bellino, Liu-Ying Luo, Ignace Vergote, Alfthan Henrik, Eleftherios P Diamandis, Henk de Bruijn, Ate G J van der Zee, The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis Cancer Research. ,vol. 63, pp. 807- 811 ,(2003)
Charles Drescher, John Raycraft, Martin McIntosh, Martha Hayden-Ledbetter, Nicole Urban, Michèl Schummer, Karl Erik Hellström, Jeffrey A Ledbetter, Ingegerd Hellström, The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma Cancer Research. ,vol. 63, pp. 3695- 3700 ,(2003)
M. A. Bookman, GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma Journal of Clinical Oncology. ,vol. 24, pp. 5002- 5002 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.5002
A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, M. J. Thun, Cancer statistics, 2007. CA: A Cancer Journal for Clinicians. ,vol. 57, pp. 43- 66 ,(2007) , 10.3322/CANJCLIN.57.1.43
Jonathan S. Berek, Catherine Chung, Klara Kaldi, Joanna M. Watson, Reba M. Knox, Otoniel Martínez-Maza, Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer American Journal of Obstetrics and Gynecology. ,vol. 164, pp. 1038- 1043 ,(1991) , 10.1016/0002-9378(91)90582-C
R. T. Penson, K. Kronish, Z. Duan, A. J. Feller, P. Stark, S. E. Cook, L. R. Duska, A. F. Fuller, A. K. Goodman, N. Nikrui, K. M. MacNeill, U. A. Matulonis, F. I. Preffer, M. V. Seiden, Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. International Journal of Gynecological Cancer. ,vol. 10, pp. 33- 41 ,(2000) , 10.1046/J.1525-1438.2000.00003.X
Román Peréz-Soler, Leonard Saltz, Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Journal of Clinical Oncology. ,vol. 23, pp. 5235- 5246 ,(2005) , 10.1200/JCO.2005.00.6916